Results 141 to 150 of about 17,579 (227)

Hepatitis C Virus NS5A Inhibits YAP1-HSC70 Interaction, Thereby Preventing YAP1 Degradation Via Chaperone-Mediated Autophagy. [PDF]

Kobe J Med Sci
Septianastiti MA, Matsui C, Xu Z, Puspitasari F, Deng L, Abe T, Shoji I.   +6 more
europepmc   +1 more source

Deep Sequencing Analysis of Hepatitis C Virus Subtypes and Resistance-Associated Substitutions in Genotype 4 Patients Resistant to Direct-Acting Antiviral (DAA) Treatment in Egypt. [PDF]

Int J Mol Sci
Garcia-Cehic D, Mosbeh A, A Gad H, Gomaa AI, Ibañez Lligoña M, Gregori J, Colomer-Castell S, Campos C, Rodriguez-Frias F, Esteban JI, Kohla MS, Abdel-Rahman MH, Quer J.   +12 more
europepmc   +1 more source

Mechanistic and Kinetic Insights into the Acylation Reaction of Hepatitis C Virus NS3/NS4A Serine Protease with NS4B/5A Substrate. [PDF]

Biomolecules
Martínez-González JÁ, Salazar-Sanchez N, Larriva-Hormigos M, Martínez R, González M.   +4 more
europepmc   +1 more source

A Quinoline Derivative HZ-6d Induces Antiviral Activity Against Hepatitis C Virus Via Apoptosis-Mediated Cytotoxicity. [PDF]

Kobe J Med Sci
Suwardana GNR, Rhamadianti AF, Abe T, Deng L, Matsui C, Yasui M, Takeda N, Yamada T, Ueda M, Shoji I.   +9 more
europepmc   +1 more source

Visualising viral interactions and mechanisms at the nanoscale with expansion microscopy. [PDF]

Npj Viruses
Övermöhle L, Baum M, Bhatia R, Byskata K, Scherer KM.   +4 more
europepmc   +1 more source

Genetic Characterization of Hepatitis C Virus Among People Who Use Crack Cocaine: A Study Conducted on the Brazilian Amazon Coast. [PDF]

Pathogens
Heymbeeck JAA, do Nascimento WL, Freitas MCS, de Sousa Rocha L, Costa FF, de Queiroz JPQ, Simeone D, Martins LC, Machado LFA, Fischer B, Kupek E, Oliveira-Filho AB.   +11 more
europepmc   +1 more source

Receptor transporter protein 4 (RTP4)-mediated repression of hepatitis C virus replication in mouse cells. [PDF]

PLoS Pathog
Schwoerer MP, Carver S, Lin AE, Liu J, Cafiero TR, Berggren KA, Dhawan S, Suzuki S, Heller B, Rodriguez C, O'Connell AK, Gertje HP, Crossland NA, Ploss A.   +13 more
europepmc   +1 more source

Hepatitis C: current treatments, emerging therapies and tackling health inequities on the path to global elimination. [PDF]

Clin Med (Lond)
Farooq HZ, Foster GR.
europepmc   +1 more source

Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes. [PDF]

Viruses
AlKaabi H, AlSinani S, El-Kassas M, Alswat KA, AlNaamani KM.   +4 more
europepmc   +1 more source

Molecular mechanism of highly potent NS5A inhibitors [PDF]

Hepatitis C is responsible for causing chronic infections in over 170 million people all over the world who are at a risk of developing into liver cirrhosis and hepatocellular carcinoma, locating HCV in a major public health burden. Until recently, the standard-of care treatment consisted of Interferon-alpha and ribavirin, in addition to non-structural
openaire